atrasentan has been researched along with Diabetes Mellitus, Adult-Onset in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (16.13) | 29.6817 |
| 2010's | 14 (45.16) | 24.3611 |
| 2020's | 12 (38.71) | 2.80 |
| Authors | Studies |
|---|---|
| Bakris, GL; Correa-Rotter, R; de Zeeuw, D; Gansevoort, RT; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, DE; Makino, H; McMurray, JJV; Parving, HH; Perkovic, V; Tobe, S; Waijer, SW | 1 |
| Bakris, GL; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Hou, FF; Januzzi, JL; Kitzman, DW; Kohan, DE; Kolansky, DM; Koomen, J; Makino, H; McMurray, JJV; Parving, HH; Perkovic, V; Smeijer, JD; Tobe, S | 1 |
| Benito, B; Bermejo, S; Dominguez-Báez, P; Jacobs-Cacha, C; Llorens-Cebria, C; Martinez-Diaz, I; Martos, N; Ortiz, A; Pieper, MP; Soler, MJ; Van den Bosch, MM; Vergara, A | 1 |
| Barratt, J; Heerspink, HJL; Kohan, DE; Liew, A; Tang, SCW | 1 |
| Chan, KW; de Zeeuw, D; Gansevoort, RT; Heerspink, HJL; Jongs, N; Kohan, DE; Liew, A; Schechter, M; Smeijer, JD; Tang, SCW; Vart, P; Wanner, C | 1 |
| Correa-Rotter, R; de Zeeuw, D; Gansevoort, RT; Ju, W; Kohan, DE; Lambers Heerspink, HJ; Liew, A; Rossing, P; Smeijer, JD; Tang, SCW | 1 |
| Liu, D; Liu, Z | 1 |
| Libetta, C; Sepe, V | 1 |
| Alpers, CE; Hudkins, KL; Steegh, F; Wietecha, TA | 1 |
| Chi, J; Dong, B; Huang, Y; Lv, W; Wang, YG; Zhou, Y | 1 |
| Bakris, G; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, D; Koomen, JV; Makino, H; McMurray, JJV; Parving, HH; Perkovic, V; Stevens, J; Tobe, SW | 1 |
| Bakris, G; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, DE; Koomen, JV; Makino, H; McMurray, JJV; Parving, HH; Perkovic, V; Stevens, J; Tobe, SW | 1 |
| Andress, D; Brennan, JJ; Busch, R; Coll, B; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Houser, M; Kohan, D; Makino, H; Parving, HH; Pergola, P; Perkovic, V; Pritchett, Y; Remuzzi, G; Tobe, SW; Toto, R; Webb, DJ | 1 |
| Andress, DL; Bakris, G; Brennan, JJ; Correa-Rotter, R; de Zeeuw, D; Dey, J; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, D; Makino, H; McMurray, J; Parving, HH; Perkovic, V; Tobe, S; Wigderson, M | 1 |
| de Zeeuw, D; Heerspink, HJL; Koomen, JV; Mostafa, NM; Parving, HH; Stevens, J | 1 |
| Andress, DL; Bakris, G; Brennan, JJ; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, D; Makino, H; McMurray, J; Parving, HH; Perkovic, V; Tobe, S; Wigderson, M; Yi, T | 1 |
| Heerspink, HJL; Muskiet, MHA; Wheeler, DC | 1 |
| Tuttle, KR | 1 |
| Brenner, S; Wanner, C | 1 |
| Pollock, DM; Pollock, JS | 1 |
| Andress, D; Brennan, JJ; Coll, B; Correa-Rotter, R; de Zeeuw, D; Houser, M; Kohan, D; Lambers Heerspink, HJ; Makino, H; Parving, HH; Perkovic, V; Pritchett, Y; Remuzzi, G; Tang, H; Tobe, SW; Toto, R; Viberti, G | 1 |
| Andress, D; Brennan, JJ; Coll, B; Correa-Rotter, R; de Zeeuw, D; Hou, FF; Kitzman, DW; Kohan, DE; Lambers Heerspink, HJ; Makino, H; Parving, HH; Perkovic, V; Remuzzi, G; Tobe, SW; Toto, R | 1 |
| Andress, D; Brennan, JJ; Coll, B; Correa-Rotter, R; de Zeeuw, D; Hoekman, J; Hou, FF; Kitzman, DW; Kohan, D; Lambers Heerspink, HJ; Makino, H; Parving, HH; Perkovic, V; Remuzzi, G; Schievink, B; Smink, PA; Tobe, S; Toto, R | 1 |
| Andress, D; Brennan, JJ; Coll, B; Correa-Rotter, R; Davis, JW; de Zeeuw, D; Heerspink, HJ; Idler, K; Kohan, DE; Liu, M; Makino, H; Parving, HH; Perkovic, V; Remuzzi, G; Tobe, SW; Toto, R | 1 |
| Ergul, A; Li, W; Sachidanandam, K | 1 |
| Andress, DL; Brennan, J; Coll, B; Kohan, DE; Molitch, M; Pritchett, Y | 1 |
| Dorrance, AM; Ergul, A; Fagan, SC; Harris, AK; Hutchinson, JR; Johnson, MH; Sachidanandam, K; Stepp, DW | 1 |
| Ergul, A; Harris, AK; Hutchinson, J; Imig, JD; Johnson, MH; Pollock, DM; Portik-Dobos, V; Song, W | 1 |
| Ergul, A; Song, W | 1 |
| Elgebaly, MM; Ergul, A; Harris, AK; Li, W; Sachidanandam, K | 1 |
| Elgebaly, MM; Ergul, A; Harris, AK; Hutchinson, JR; Mezzetti, EM; Portik-Dobos, V; Sachidanandam, K | 1 |
2 review(s) available for atrasentan and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
Topics: Albuminuria; Atrasentan; Bosentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin Receptor Antagonists; Heart Failure; Humans; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic | 2021 |
New pharmacological strategies for protecting kidney function in type 2 diabetes.
Topics: Antihypertensive Agents; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin Receptor Antagonists; Humans; Hypoglycemic Agents; Incretins; Mineralocorticoid Receptor Antagonists; Naphthyridines; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
14 trial(s) available for atrasentan and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A
Topics: Albuminuria; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Renal Insufficiency; Renal Insufficiency, Chronic | 2021 |
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.
Topics: Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Natriuretic Peptide, Brain; Renal Insufficiency, Chronic; Weight Gain | 2022 |
Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atrasentan; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelin Receptor Antagonists; Humans; Pain; Renal Insufficiency, Chronic | 2023 |
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial.
Topics: Albuminuria; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Glomerular Filtration Rate; Humans; Kidney | 2021 |
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.
Topics: Aged; Area Under Curve; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Endothelin Receptor Antagonists; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Failure, Chronic; Male; Middle Aged; Treatment Outcome | 2021 |
Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Aged; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Edema; Electric Impedance; Endothelin Receptor Antagonists; Female; Humans; Longitudinal Studies; Male; Middle Aged; Pyrrolidines; Renin-Angiotensin System; Weight Gain | 2017 |
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Humans; Kidney; Kidney Failure, Chronic; Male; Precision Medicine; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Research Design; Severity of Illness Index | 2018 |
Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrasentan; Biological Variation, Population; Biomarkers; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Humans; Metabolic Clearance Rate; Renal Elimination; Renal Insufficiency; Severity of Illness Index; Sodium | 2018 |
Baseline characteristics and enrichment results from the SONAR trial.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diuretics; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Glomerular Filtration Rate; Humans; Hypertension; Male; Middle Aged; Precision Medicine; Renal Insufficiency; Risk | 2018 |
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrasentan; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Endothelin-1; Female; Humans; Kidney Function Tests; Lipids; Male; Middle Aged; Pyrrolidines | 2014 |
Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy.
Topics: Aged; Albuminuria; Atrasentan; Body Fluids; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Endothelin Receptor Antagonists; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Pyrrolidines; Weight Gain | 2015 |
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.
Topics: Aged; Atrasentan; Biomarkers; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Male; Middle Aged; Pyrrolidines; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2016 |
Comparison of exposure response relationship of atrasentan between North American and Asian populations.
Topics: Aged; Albuminuria; Asia; Asian People; Atrasentan; Bilirubin; Body Fluids; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; North America; Pyrrolidines; Treatment Outcome; Weight Gain; White People | 2017 |
Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).
Topics: Aged; Albuminuria; Atrasentan; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Edema; Endothelin A Receptor Antagonists; Female; Glomerular Filtration Rate; Hispanic or Latino; Humans; Male; Middle Aged; Pyrrolidines; Renal Insufficiency, Chronic; Renin-Angiotensin System | 2012 |
15 other study(ies) available for atrasentan and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice.
Topics: Animals; Atrasentan; Blood Glucose; Diabetes Mellitus, Type 2; Endothelin Receptor Antagonists; Mice; Ramipril; Receptors, Endothelin; Renin-Angiotensin System; Sodium-Glucose Transporter 2 | 2022 |
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease.
Topics: Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney; Liver; Renal Insufficiency, Chronic | 2023 |
Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease.
Topics: Atrasentan; Diabetes Mellitus, Type 2; Endothelin Receptor Antagonists; Humans; Insulin Resistance; Kidney; Renal Insufficiency, Chronic | 2023 |
Atrasentan in patients with diabetes and chronic kidney disease.
Topics: Atrasentan; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Kidney; Renal Insufficiency, Chronic | 2020 |
Atrasentan in patients with diabetes and chronic kidney disease.
Topics: Atrasentan; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Kidney; Renal Insufficiency, Chronic | 2020 |
Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Losartan; Mice; Phosphorylation; Podocytes; Proteinuria; Renin-Angiotensin System; Ribosomal Protein S6 Kinases; TOR Serine-Threonine Kinases | 2020 |
A turning point for chronic kidney disease in diabetes.
Topics: Atrasentan; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Kidney; Renal Insufficiency, Chronic | 2019 |
[Diabetic Kidney Disease - How to Protect the Kidney?]
Topics: Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin A Receptor Antagonists; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
SONAR propels endothelin A receptor antagonists to success.
Topics: Atrasentan; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelin A Receptor Antagonists; Humans; Renal Insufficiency, Chronic | 2019 |
Comparison of selective versus dual endothelin receptor antagonism on cerebrovascular dysfunction in diabetes.
Topics: Animals; Atrasentan; Bosentan; Cerebral Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Male; Pyrrolidines; Rats; Rats, Inbred Strains; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Vasodilator Agents | 2011 |
Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1.
Topics: Animals; Atrasentan; Blood Glucose; Cerebral Arteries; Collagen; Diabetes Mellitus, Type 2; Endothelin A Receptor Antagonists; Endothelin-1; Gene Expression Regulation; Matrix Metalloproteinases; Neovascularization, Physiologic; Pyrrolidines; Rats; Telencephalon | 2005 |
Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes.
Topics: Animals; Atrasentan; Blood Glucose; Diabetes Mellitus, Type 2; Endothelins; ErbB Receptors; Fibronectins; Gene Expression Regulation, Enzymologic; Kidney; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Phosphorylation; Pyrrolidines; Rats; Rats, Inbred Strains; Transcriptional Activation | 2006 |
Type-2 diabetes-induced changes in vascular extracellular matrix gene expression: relation to vessel size.
Topics: Animals; Aorta; Atrasentan; Blood Vessels; Diabetes Mellitus, Type 2; Endothelin Receptor Antagonists; Endothelin-1; Gene Expression Profiling; Gene Expression Regulation; Hyperglycemia; Male; Matrix Metalloproteinases; Mesenteric Arteries; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Pyrrolidines; Rats; Rats, Wistar; Reference Values | 2006 |
Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes.
Topics: Acetylcholine; Animals; Atrasentan; Basilar Artery; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Male; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents; Viper Venoms | 2008 |
Effect of chronic and selective endothelin receptor antagonism on microvascular function in type 2 diabetes.
Topics: Acetylcholine; Animals; Atrasentan; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Male; Mesenteric Arteries; Microcirculation; Myography; Peptides, Cyclic; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Up-Regulation; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents; Viper Venoms | 2008 |